API | inotuzumab ozogamicin

inotuzumab ozogamicin (besponsa) Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA First in Class

AACT ChEMBL DrugBank Drugs@FDA MeSH

Active Ingredient History

NOW

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
inotuzumab ozogamicin

More Chemistry

Pharmacology

Mechanisms of Action:
- B-cell receptor CD22 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: ozogamicin
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

Australia

$10163.5938

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

besponsa | cmc544 | cmc 544 | cmc-544 | inotuzumab ozogamicin | inotuzumab ozogamycin | pf-05208773 | way-207294 | way-207294 cmc-544

Organizations (47)

Research & Development (47)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (19)

Approved Indications (1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications - Clinical Trial Phases 1-4 (19)

Antigens, CD (Phase 2)

Bone Marrow Cells (Phase 1/Phase 2)

Burkitt Lymphoma (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)

Leukemia (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 1/Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Testicular Neoplasms (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 45
# of Trial Organizations: 47

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue

Clinical Drug Experience Knowledgebase